Navigation Links
Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
Date:2/12/2013

" said Bob Duggan , CEO and Chairman of the Board. "This compound entered the clinic in 2009 and has demonstrated tremendous clinical progress over the past four years. I would like to thank our collaboration partner, Janssen, for their support. Together we are committed to bringing this new therapeutic to patients and health care providers."

Dr. Ellen Sigal , Chair & Founder of Friends of Cancer Research, a think tank and advocacy organization based in Washington, D.C., said, "As an oncology product, ibrutinib receiving the Breakthrough Therapy Designation is an example of progress and hope for patients fighting a range of cancers. This designation shows that the FDA is dedicated to using an 'all hands on deck approach' to work on products that show promise in treating serious and life-threatening diseases. The breakthrough pathway that our organization worked to create is intended to speed up the development and review of treatments that may demonstrate substantial improvement over existing therapies, and ibrutinib is a great example of using this new designation to potentially accelerate patient access to promising treatments."

The FDA Breakthrough Therapy Designation for ibrutinib in MCL patients was based on data from clinical and pre-clinical studies. Ibrutinib has the potential to improve the outcome in this serious and life-threatening disease which has a poor prognosis. The company and Janssen have designed a comprehensive development program of ibrutinib in MCL which includes the following studies:
- A Phase III randomized, multi-center registration trial of ibrutinib as a monotherapy versus temsirolimus in relapsed or refractory MCL patients who received at least one prior rituximab-containing chemotherapy regimen, RAY (MCL3001).
- A Phase III randomized, double-blind, placebo-controlled study of ibrutinib plus bendamustine and rituximab
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
2. Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
3. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
4. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
5. Landauer, Inc. Reports Fiscal 2013 First Quarter Results
6. Misonix Reports Financial Results for First Half of Fiscal 2013
7. CareFusion Reports First Half Fiscal 2013 Results
8. Avanir Pharmaceuticals Reports Fiscal 2013 First Quarter Financial And Business Results
9. American Pacific Reports Fiscal 2013 First Quarter Results; Reaffirms Full Year Guidance
10. European patient registry in venous thromboembolism (VTE) - PREFER in VTE - enrols first patient
11. Neutronic Ear Introduces Worlds First Rechargeable-Powered Hearing Device
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... 2, 2015  Maquet Medical Systems ... signed an exclusive distribution agreement with Flight Medical ... the Flight 60 mechanical ventilator. The Flight 60 ... and affordable mobility. Starting in the first quarter ... in the United States ...
(Date:3/2/2015)... , March 2, 2015 Valencia Technologies ... th patient with its radically small device for ... 2015. Valencia,s early results in this randomized, double-blinded, controlled trial ... degree of confidence that it will succeed in a ... its early clinical results, Valencia ...
(Date:3/2/2015)... BOULDER, Colo. , March 2, 2015 /PRNewswire/ ... regarding close of their transactions, Array BioPharma Inc. ... the binimetinib and encorafenib definitive agreements with Novartis.  ... will receive an upfront payment of $85 million ... of Array, noted, "With the close of the ...
Breaking Medicine Technology:Maquet Medical Systems USA to Exclusively Distribute Flight Medical's Flight 60 Respiratory Ventilators 2Maquet Medical Systems USA to Exclusively Distribute Flight Medical's Flight 60 Respiratory Ventilators 3Valencia Technologies Implants its 48th Patient, Continues Equity Crowdfunding 2Array Announces Completion Of Binimetinib And Encorafenib Transactions 2Array Announces Completion Of Binimetinib And Encorafenib Transactions 3Array Announces Completion Of Binimetinib And Encorafenib Transactions 4Array Announces Completion Of Binimetinib And Encorafenib Transactions 5
... 5, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: ... in China, announced today the resignation of Jacob Chik Keung ... has initiated an executive search for a new Chief Financial ... with the Company until August 16, 2011.  Ms. Nan Wang, ...
... 2011 ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), ... platforms to develop treatments in areas of oncology, cancer ... full service global public relations firm, to support its ... a media communications outreach program primarily aimed at introducing ...
Cached Medicine Technology:Sinovac Announces Management Changes 2Sinovac Announces Management Changes 3Access Pharmaceuticals Retains Edelman as Public Relations Firm 2Access Pharmaceuticals Retains Edelman as Public Relations Firm 3
(Date:3/2/2015)... Over the last five years the ultrasound market has ... their geographic presence and achieve economies of scale. The ... by 2019 at CAGR of 5.1% from 2014 to ... and a major part of Europe are mature markets ... including China and India, Latin America and the Middle ...
(Date:3/2/2015)... LegitScript, LLC, operator of ... including those for Internet pharmacy certification, monitoring ... classification, has launched a certification program for ... program, called iCareRx , provides certification ... identity of the owner/operator of Internet websites, ...
(Date:3/2/2015)... WI (PRWEB) March 02, 2015 ... consultancy focused on quality, regulatory and technical consulting, ... as Chief Operating Officer. , Before joining ... experience leading R&D teams in all aspects of ... leadership positions at Covidien (Medtronic), Regulatory Compliance Associates ...
(Date:3/2/2015)... The Alliance for Bangladesh Worker Safety today announced ... serve as chief safety officer. In this role, he ... and guide remediation efforts in all factories from which ... the Alliance continues to bring world-class expertise to factory ... said Alliance Independent Chair Ellen Tauscher. “His role as ...
(Date:3/2/2015)... Aliso Viejo, California (PRWEB) March 02, 2015 ... the release of the TranStatic Volume 2 from Pixel Film ... glitch transitions made exclusively for FCPX,” said Christina Austin, CEO ... tool to have in any Final Cut Pro X editors ... one scene to the next with media altering static scrambling ...
Breaking Medicine News(10 mins):Health News:Therapeutic Ultrasound Devices Market worth $6.2 Billion by 2019 - New Research Report by MarketsandMarkets 2Health News:Therapeutic Ultrasound Devices Market worth $6.2 Billion by 2019 - New Research Report by MarketsandMarkets 3Health News:LegitScript Launches Certification Program for Internet Eyeglass Sellers 2Health News:Regulatory Compliance Associates® Inc. Welcomes Seyed Khorashahi as Chief Operating Officer 2Health News:Alliance for Bangladesh Worker Safety Names New Chief Safety Officer 2Health News:Pixel Film Studios released the TranStatic Volume 2 plugin for Final Cut Pro X today 2
... a new country is difficultlearning the cultural rules and meanings ... published in Psychological Science , a journal of the ... for children, but quickly becomes more difficult after about the ... many aspects of learning and development have a critical windowif ...
... is a great way to stay physically active while ... is that mountain biking-related injuries have decreased. A new ... Research and Policy of The Research Institute at Nationwide ... decreased 56 percent over the 14-year study period (1994 ...
... WEDNESDAY, Feb. 2 (HealthDay News) -- A large international trial finds ... as well as it protects young women. HPV is the ... linked to penile cancer and other malignancies in men. According ... New England Journal of Medicine , which was funded by the ...
... Phil predicted that spring will come on time, and NASA ... the U.S. are now anxious for the prediction to come ... over the last couple of days, including Phil,s home at ... and freezing rain this morning before it changed to snow ...
... Feb. 2 (HealthDay News) -- Researchers report that DNA analysis ... rare vascular disease, along with its genetic cause. As ... England Journal of Medicine , the debilitating, painful and progressive ... the hands and feet of patients, and in the vascular ...
... By Jenifer Goodwin HealthDay Reporter , ... autism have difficulty understanding others, intentions, new research shows. ... with autism, even those with high IQs, judge others ... maintaining relationships, the study found. Researchers from Massachusetts ...
Cached Medicine News:Health News:Younger immigrants adjust to a new culture faster than do older immigrants 2Health News:New national study finds mountain bike-related injuries down 56 percent 2Health News:Gardasil Vaccine Guards Against HPV in Boys 2Health News:GOES-13 Satellite sees Groundhog's Day on ice 2Health News:Scientists Discover Rare Vascular Disease 2Health News:Adults With Autism May Not Understand Others' Intentions 2Health News:Adults With Autism May Not Understand Others' Intentions 3
VG2 PLIF (Trapezoid) Posterior lumbar interbody fusion. Frozen preservation. Consists of two outer cortical planks, center cancellous plank, all from the same donor, held together by two press-fit co...
VG1 ALIF (Anterior) Anterior lumbar interbody fusion. Frozen freeze-dried preservation....
Allograft implants can be easily used to repair and promote the healing of a wide variety of bone and other tissue defects....
Solid cortical spacers with a natural anatomic fibular shape....
Medicine Products: